Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: TELO2

Gene summary for TELO2

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

TELO2

Gene ID

9894

Gene nametelomere maintenance 2
Gene AliasCLK2
Cytomap16p13.3
Gene Typeprotein-coding
GO ID

GO:0000723

UniProtAcc

B4DXS2


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
9894TELO2LZE4THumanEsophagusESCC3.26e-039.22e-020.0811
9894TELO2LZE7THumanEsophagusESCC5.20e-103.12e-010.0667
9894TELO2LZE8THumanEsophagusESCC3.49e-051.05e-010.067
9894TELO2LZE24THumanEsophagusESCC7.10e-182.40e-010.0596
9894TELO2LZE21THumanEsophagusESCC3.24e-022.15e-010.0655
9894TELO2LZE6THumanEsophagusESCC1.29e-021.33e-010.0845
9894TELO2P1T-EHumanEsophagusESCC1.89e-092.74e-010.0875
9894TELO2P2T-EHumanEsophagusESCC1.04e-193.80e-010.1177
9894TELO2P4T-EHumanEsophagusESCC2.52e-112.83e-010.1323
9894TELO2P5T-EHumanEsophagusESCC1.02e-081.61e-010.1327
9894TELO2P8T-EHumanEsophagusESCC7.31e-141.97e-010.0889
9894TELO2P9T-EHumanEsophagusESCC2.17e-081.03e-010.1131
9894TELO2P10T-EHumanEsophagusESCC1.82e-122.10e-010.116
9894TELO2P11T-EHumanEsophagusESCC5.01e-153.37e-010.1426
9894TELO2P12T-EHumanEsophagusESCC4.24e-315.19e-010.1122
9894TELO2P15T-EHumanEsophagusESCC7.03e-163.90e-010.1149
9894TELO2P16T-EHumanEsophagusESCC1.13e-182.49e-010.1153
9894TELO2P17T-EHumanEsophagusESCC4.48e-112.30e-010.1278
9894TELO2P19T-EHumanEsophagusESCC3.16e-084.24e-010.1662
9894TELO2P20T-EHumanEsophagusESCC5.95e-222.91e-010.1124
Page: 1 2 3 4 5 6 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0031647111EsophagusESCCregulation of protein stability223/8552298/187235.76e-251.52e-22223
GO:0050821111EsophagusESCCprotein stabilization140/8552191/187236.50e-153.61e-13140
GO:000072319EsophagusESCCtelomere maintenance99/8552131/187232.68e-121.08e-1099
GO:007189716EsophagusESCCDNA biosynthetic process127/8552180/187231.04e-113.85e-10127
GO:007190016EsophagusESCCregulation of protein serine/threonine kinase activity227/8552359/187231.12e-114.10e-10227
GO:000700418EsophagusESCCtelomere maintenance via telomerase56/855269/187231.40e-093.30e-0856
GO:001083319EsophagusESCCtelomere maintenance via telomere lengthening61/855281/187235.24e-089.37e-0761
GO:000627816EsophagusESCCRNA-dependent DNA biosynthetic process56/855275/187233.03e-074.30e-0656
GO:00719029EsophagusESCCpositive regulation of protein serine/threonine kinase activity124/8552200/187232.27e-062.61e-05124
GO:004586018EsophagusESCCpositive regulation of protein kinase activity219/8552386/187236.91e-066.97e-05219
GO:003367420EsophagusESCCpositive regulation of kinase activity260/8552467/187237.26e-067.22e-05260
GO:003220014EsophagusESCCtelomere organization99/8552159/187231.77e-051.57e-0499
GO:00319294EsophagusESCCTOR signaling79/8552126/187238.57e-056.21e-0479
GO:00320061EsophagusESCCregulation of TOR signaling63/8552104/187231.55e-037.29e-0363
GO:00320082EsophagusESCCpositive regulation of TOR signaling31/855247/187234.01e-031.62e-0231
GO:003164722LiverHCCregulation of protein stability211/7958298/187232.29e-235.01e-21211
GO:005082122LiverHCCprotein stabilization139/7958191/187231.61e-171.71e-15139
GO:000072311LiverHCCtelomere maintenance85/7958131/187231.86e-073.40e-0685
GO:000700412LiverHCCtelomere maintenance via telomerase49/795869/187231.51e-062.15e-0549
GO:00319291LiverHCCTOR signaling78/7958126/187238.49e-069.97e-0578
Page: 1 2 3 4 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa041505EsophagusESCCmTOR signaling pathway98/4205156/84655.81e-041.95e-039.97e-0498
hsa0415013EsophagusESCCmTOR signaling pathway98/4205156/84655.81e-041.95e-039.97e-0498
hsa041502LiverHCCmTOR signaling pathway95/4020156/84654.70e-041.99e-031.11e-0395
hsa0415011LiverHCCmTOR signaling pathway95/4020156/84654.70e-041.99e-031.11e-0395
hsa041504Oral cavityOSCCmTOR signaling pathway90/3704156/84652.87e-049.15e-044.66e-0490
hsa0415012Oral cavityOSCCmTOR signaling pathway90/3704156/84652.87e-049.15e-044.66e-0490
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
TELO2SNVMissense_Mutationnovelc.981N>Tp.Gln327Hisp.Q327HQ9Y4R8protein_codingtolerated(0.13)benign(0.007)TCGA-AC-A8OR-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
TELO2SNVMissense_Mutationnovelc.2236G>Ap.Ala746Thrp.A746TQ9Y4R8protein_codingtolerated(1)benign(0.012)TCGA-AN-A046-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
TELO2SNVMissense_Mutationrs367975943c.1372N>Ap.Val458Ilep.V458IQ9Y4R8protein_codingtolerated(0.21)benign(0.003)TCGA-BH-A1FH-01Breastbreast invasive carcinomaFemale<65III/IVUnknownUnknownPD
TELO2insertionFrame_Shift_Insnovelc.153_154insAAACCATCGGTGGCCCCCAGGCTCCCCTTGTCAAp.Glu52LysfsTer239p.E52Kfs*239Q9Y4R8protein_codingTCGA-A8-A0A6-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapyepirubicinCR
TELO2deletionFrame_Shift_Delnovelc.1774delGp.Ala592ProfsTer4p.A592Pfs*4Q9Y4R8protein_codingTCGA-EW-A2FV-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapydocetaxelSD
TELO2deletionFrame_Shift_Delc.1934delTp.Leu645ArgfsTer68p.L645Rfs*68Q9Y4R8protein_codingTCGA-GM-A2DH-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapytaxolCR
TELO2SNVMissense_Mutationnovelc.1225G>Ap.Val409Metp.V409MQ9Y4R8protein_codingdeleterious(0)probably_damaging(0.992)TCGA-2W-A8YY-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
TELO2SNVMissense_Mutationnovelc.605C>Gp.Ser202Cysp.S202CQ9Y4R8protein_codingdeleterious(0)possibly_damaging(0.707)TCGA-VS-A952-01Cervixcervical & endocervical cancerFemale>=65I/IIUnknownUnknownSD
TELO2SNVMissense_Mutationrs141078050c.1073G>Ap.Arg358Hisp.R358HQ9Y4R8protein_codingtolerated(0.38)benign(0.001)TCGA-AA-3947-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
TELO2SNVMissense_Mutationnovelc.687N>Tp.Glu229Aspp.E229DQ9Y4R8protein_codingtolerated(0.23)possibly_damaging(0.629)TCGA-AA-A010-01Colorectumcolon adenocarcinomaFemale<65I/IIChemotherapyfolinicCR
Page: 1 2 3 4 5 6 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1